‘Blantyre and L1 Health have just added to the cocktail of what Ascendis could potentially become in the next 12 to 18 months’ – Small-cap analyst Anthony Clarke.
‘Blantyre and L1 Health have just added to the cocktail of what Ascendis could potentially become in the next 12 to 18 months’ – Small-cap analyst Anthony Clarke.